Announcement
25.10.2011
On 27 September 2011, NeuroSearch announced a comprehensive restructuring of the company’s operations in order to optimise financial and managerial resources to complete the development of Huntexil®. A controlled discontinuation of other activities was announced to take place, including a gradual wind down of research activities in both the NsDiscovery division in Ballerup and in NeuroSearch Sweden AB in Gothenburg.
Consequently, as of today, Thomas Varming, EVP, NsDiscovery, and Nicholas Waters, EVP, NeuroSearch Sweden AB, have resigned from the executive management group.
Patrik Dahlen, CEO of NeuroSearch, commented:
“I wish to thank both Thomas and Nicholas for their valuable contributions to NeuroSearch over the years and wish them the best of success in their future endeavours.”
Patrik Dahlen
CEO
Contact persons
Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S (NEUR) and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is primarily to complete the development and subsequently to market Huntexil®, a unique drug in Phase III for the treatment of the motor symptoms of Huntington’s disease.
